Cyclowest Pipeline Overview
Pioneering Radiopharmaceutical Solutions with General Electric (GE)
At Cyclowest, we are dedicated to advancing nuclear medicine through the development of next-generation radiopharmaceuticals. In collaboration with General Electric (GE), we are expanding our capabilities in the production of Copper-64, Gallium-68, and Zirconium-89 agents—three critical isotopes that are transforming precision imaging and therapeutic applications.
Revolutionary
Enhancing Diagnostic Accuracy with Copper-64
Copper-64 has emerged as a highly valuable isotope in positron emission tomography (PET) imaging. Its extended half-life and versatile chemistry allow for superior radiolabeling, making it an excellent choice for targeted diagnostics and theranostic applications. Our partnership with GE enables us to scale production, ensuring reliable access to this isotope for research and clinical use.
Revolutionising Molecular Imaging with Gallium-68
Gallium-68 is a well-established isotope used in PET scans to detect a range of cancers, particularly neuroendocrine tumours and prostate cancer. Through our collaboration with GE, we are refining the production process to enhance its availability, improving patient outcomes by providing superior imaging agents for early and precise diagnosis.
Cyclowest is also collaborating with BioTech companies, a leader in precision oncology, to develop Zirconium-based diagnostic agents. This partnership focuses on targeting cancer-specific biomarkers, enhancing the effectiveness of PET imaging in detecting and monitoring tumours.
Development of Zirconium Agents with BioTech Companies
Advancing Cancer Detection and Treatment
Zirconium-labelled monoclonal antibodies are transforming how we diagnose and track cancer progression. Our work with BioTech companies aims to improve the sensitivity and specificity of these agents, ensuring they deliver accurate imaging results that guide targeted therapies.
Bringing Next-Generation Imaging to Market
By leveraging Cyclowest’s expertise in radiopharmaceutical manufacturing, we are ensuring that Zirconium-based agents meet the highest GMP standards. These innovations are expected to set new benchmarks in cancer diagnostics, ultimately leading to better patient care and more personalised treatment approaches.
Shaping the Future of Nuclear Medicine
At Cyclowest, our collaborations with General Electric (GE), Sumitomo and BioTech companies reinforce our commitment to driving progress in nuclear medicine. Through the development of Copper-64, Gallium-68, and Zirconium-89 agents, we are expanding the possibilities for both diagnostics and therapeutic applications, ensuring that healthcare providers and researchers have access to the most advanced radiopharmaceutical solutions available today.